In Vitro Immunization for the Generation of Hybridomas Using Serum-Free Medium

  • Frederick J. Darfler
Part of the Contemporary Biomedicine book series (CB, volume 7)


No one engaged in research in the biological sciences is unaware of the impact that monoclonal antibodies have had as research tools. These proteins recognize specific sites on a single antigen and often bind to these sites with high affinity. Because of this, researchers have found many uses for monoclonal antibodies, including their application in immunoassays (1), purification or identification of cellular proteins (2,3), and studies of enzyme action (4). The significance of monoclonal antibodies was recently acknowledged when the 1984 Nobel prize was shared by the co-inventors of the B-B-cell hybridoma, Kohler and Milstein (5). As the commercial applications of monoclonal antibodies begin to grow, newer and better techniques for hybridoma formation will be necessary to meet the demand for antibodies with unique, well-defined specificities and distinctive immunological and physical properties. One approach to the improvement of hybridoma formation techniques is to attempt to define the components and reaction conditions that result in maximal formation of antibody-secreting hybridomas. Until recently, all aspects of in vitro immunization and hybridoma formation have involved an ill-defined component—animal serum, usually fetal bovine serum.


Conditioned Medium Spleen Cell Lymphoid Cell Ammonium Sulfate Precipitation Fusion Frequency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Siddle K.: 1984. Clinical assays of products of normal and malignant cells. Br. Med. Bull. 40: 276–282.PubMedGoogle Scholar
  2. 2.
    Parkhouse R. M. E.: 1984. Immunopurification. Br. Med. Bull. 40: 297–301.PubMedGoogle Scholar
  3. 3.
    Furth M. E„ Davis L. J., Fleurdelys B., and Scolnick E. M.: 1982. Monoclonal antibodies o the p21 products of the transforming gene of Harvey murine sacona virus and of the cellular ras gene family. J. Virol. 43: 294–304.PubMedGoogle Scholar
  4. 4.
    Lennox E. S.: 1984. Clinical Applications of monoclonal antibodies; Introduction. Br. Med. Bull. 40: 207–208.Google Scholar
  5. 5.
    Kohler G. and Milstein C.: 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497.PubMedCrossRefGoogle Scholar
  6. 6.
    Darfler F. J. and Insel P. A.: 1983. Clonal growth of lymphoid cells in serum-free media requires elimination of H2O2 toxicity. J. Cell. Physiol. 115: 31–36.PubMedCrossRefGoogle Scholar
  7. 7.
    Arai S., Yamane I., Tannik Y., and takishima T.: 1977. Role of bovine serum albumin in blastoid transformation of lymphocytes by phytohemagglutinin. Proc. Soc. Exp. Biol. Med. 154: 444–448.PubMedGoogle Scholar
  8. 8.
    Uittenbogaart C. H., Cantor Y., and Fahey J. L.: 1983. Growth of human malignant lymphoid cells lines in serum-free medium. In Vitro 19: 67–72.PubMedCrossRefGoogle Scholar
  9. 9.
    Spieker-Polet H. and Polet H.: 1981. Requirement of a combination of a saturated and unsaturated free fatty acid and a fatty acid carrier protein for in vitro growth of lymphocytes. J. Immunol. 126: 949–956.PubMedGoogle Scholar
  10. 10.
    Iscove M. N. and.Melchers F.: 1978. Complete replacement of serum using albumin, transferrin, and soybean lipid in cultures of lipopolvsaccharide-reactive B lymphocytes. J. Exp. Med. 147: 923–933.PubMedCrossRefGoogle Scholar
  11. 11.
    Iscove, N. N., Guilbert L. J., and Weyman C.: 1980. Complete replacement of serum in primary cultures of erythropoietin-dependent red cell precursors (CFU-E) by albumin, transferrin, iron, unsaturated fatty acid, lecithin, and cholesterol. Exp. Cell Res. 126: 121–126.PubMedCrossRefGoogle Scholar
  12. 12.
    Murakami H., Masui H., Sato G. H., Sueoka N„ and Chow T. P.: 1982. Ethanolamine is an essential component for the growth of hybridomas. Proc. Natl. Acad. Sci. USA 79: 1158–1162.PubMedCrossRefGoogle Scholar
  13. 13.
    Chang T. J., Steplewski Z., and Koprowski J.: 1980. Production of monoclonal antibodies in serumfree medium. J. Immunol. Metli. 39: 369–375.CrossRefGoogle Scholar
  14. 14.
    Mendelsohn J., Caviles Jr., A., and Castagnola J.: 1984. Culture of human lymphocytes in serum-free medium. In Methods for Serum-Free Culture of Neuronal and Lymphoid Cells, ( D. Barnes, D. A. Sirbasku, and G. H. Sato, eds.) New York, Plenum.Google Scholar
  15. 15.
    Darfler F. J. : 1985. In vitro immunization and hybridoma formation using serum-free medium. Submitted for publication.Google Scholar
  16. 16.
    Kennet R. H., Denis K. A., Tung A. S., and Klinman N. R.: 1978. Hybrid plasmacytoma production: fusion with adult spleen cells, monoclonal spleen fragments, neonatal spleen cells and human spleen cells. Curr. Top. Microbiol. Immunol. 81: 77–84.Google Scholar
  17. 17.
    Mishell B. B. and Shigi S. M.: 1980. In Selected Methods in Cellular Immunology, San Francisco, W. H. Freeman.Google Scholar
  18. 18.
    Van Ness J.: 1984. Immunization in vitro and production of monoclonal antibodies specific to insoluble and weakly immunogenic proteins. Proc. Natl. Acad. Sci. USA 81: 7897–7914.PubMedCrossRefGoogle Scholar
  19. 19.
    Commercial Biotechnology: An International Analysis, US Congress, Office of Technology Assessment, Washington D.C., February 1984.Google Scholar

Copyright information

© The Humana Press Inc. 1987

Authors and Affiliations

  • Frederick J. Darfler

There are no affiliations available

Personalised recommendations